Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093428 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03093428 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants.
The verdict
NCT03093428, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Radium-223 * Pembrolizumab
Interventions
- DRUG Pembrolizumab
- DRUG Radium-223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-06-09 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093428
The ClinicalTrials.gov registry entry for NCT03093428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03093428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03093428 about?
NCT03093428 is a clinical study titled "Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC". This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Radium-223 * Pembrolizumab
What is the current status of trial NCT03093428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-06-09. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT03093428?
The interventions under investigation include: Pembrolizumab (DRUG), Radium-223 (DRUG).
Who is sponsoring clinical trial NCT03093428?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.